Advertisements
Feeds:
Posts
Comments

Archive for the ‘BioMed e-Books e-Series by LPBI Group’ Category


Royalties in Kindle Unlimited and Kindle Owners’ Lending Library – A guide to publishing on Amazon

 

Royalties in Kindle Unlimited and Kindle Owners’ Lending Library

You’re eligible for royalty payment from Kindle Unlimited (KU, or Abonnement Kindle in France) and the Kindle Owners’ Lending Library (KOLL) for pages an individual customer reads in your book for the first time. A guide to publishing on Amazon

A customer can read your book as many times as they like, but we will only pay you for the number of pages read the first time the customer reads them. It may take months for customers to read pages in your book, but no matter how long it takes, we’ll still pay you once it happens. This is true even if your KDP Select enrollment period has expired, and you choose not to re-enroll.

Kindle Edition Normalized Page Count (KENPC v3.0)

To determine a book’s page count in a way that works across genres, devices, and display settings, we developed the Kindle Edition Normalized Page Count (KENPC). KENPC is calculated using standard formatting settings (font, line height, line spacing, etc.). We use KENPC to measure the number of pages customers read in your book, starting with the Start Reading Location (SRL) to the end of your book. Amazon typically sets SRL at chapter 1 so readers can start reading the core content of your book as soon as they open it. Non-text elements within books including images, charts and graphs will count toward a book’s KENPC.

KENPC v3.0
We released KENPC v3.0 to improve the way we measure how many pages of each book Kindle Unlimited and KOLL customers read. We’re constantly working to improve our programs and increase fairness of how we allocate the KDP Select Global Fund. These changes continue to improve the program and reward authors whose books are being borrowed and read the most by customers.

The KENPC v3.0 update applies uniformly to all KDP Select books and all versions of those books. Regardless of which version a customer may be reading, all future royalties will be paid using KENPC v3.0. If a customer previously borrowed your book and is still reading it, any new pages read will be based on KENPC v3.0.

Authors are able to earn a maximum of 3,000 Kindle Edition Normalized Pages (KENPs) read per title per customer. This means that each time your book is borrowed and read, you will receive credit for up to 3,000 pages. We believe this results in an equitable distribution of the KDP Select Global Fund.

Your book’s KENPC
You can see your book’s KENPC v3.0 listed on the “Promote and Advertise” page in your Bookshelf, and you can also see total pages read on your Sales Dashboard report. Because it’s based on default settings, KENPC v3.0 may vary from page counts listed on your Amazon detail page, which are derived from other sources.

KDP Select Global Fund
Our total payout from the KDP Select Global Fund will be unaffected by the transition to KENPC v3.0, and the amount you earn from the global fund will continue to be determined based on your share of total pages read by Kindle Unlimited (KU) and Kindle Owners’ Lending Library (KOLL) customers. The new KENPC version will be applied uniformly to all KDP Select books and used to measure all pages read.

 

Royalties

You’ll get one combined royalty payment for both KU and KOLL, paid according to the same payment schedule and payment method you selected for your other KDP sales.We review the size of the KDP Select Global Fund each month in order to make it compelling for authors to enroll their books in KDP Select. We announce the fund monthly in our community forum on kdp.amazon.com.The share of fund allocated to each country varies based on a number of factors, such as exchange rates, customer reading behavior, and local subscription pricing. Author earnings are then determined by their share of total pages read, up to a total of 3,000 pages per customer per title.

For example, here’s how we’d calculate royalty payout if $10 million in funds were available in a given month with 100 million total pages read (Note: Actual payouts vary and may be less; check your Prior Month’s Royalty Report to see your earnings):

  • Author with a 100 page bookthat was borrowed and read completely 100 times would earn $1,000 ($10 million multiplied by 10,000 pages for this author divided by 100,000,000 total pages).
  • Author of a 200 page bookthat was borrowed and read completely 100 times would earn $2,000 ($10 million multiplied by 20,000 pages for this author divided by 100,000,000 total pages).
  • Author of a 200 page bookthat was borrowed 100 times but only read halfway through on average would earn $1,000 ($10 million multiplied by 10,000 pages for this author divided by 100,000,000 total pages).

We always support our authors’ efforts to promote their books, but at the same time we work to prevent any manipulation of the Kindle platform.

We do not permit authors to offer, or participate in marketing that incentivizes Kindle Unlimited or Kindle Owners’ Lending Library customers to read their books in exchange for compensation of any kind. This includes payment (whether in the form of money or gift certificates), bonus content, entry to a contest or sweepstakes, discounts on future purchases, extra product, or other gifts.

Because we’re always looking to improve our authors’ experience, we have systems in place to monitor for potential manipulation.

 

Reporting

You can see your Kindle Edition Normalized Pages (KENP) Read in your Sales Dashboard report by marketplace and title. To see historical pages read, click “Generate Report” from your Sales Dashboard and go to the Orders Report tab.

If you’re enrolled in KDP Select, you will also see the following data on your reports:

Month-To-Date Unit Sales Report: The number of pages Kindle Unlimited or KOLL customers read of your books, under the “Kindle Edition Normalized Pages (KENP) Read” column.

Prior Months’ Royalties Report: For every title, there are five possible transaction types:

  • 35%:Amount a title earned under the 35% royalty option

  • 70%:Amount a title earned under the 70% royalty option

  • KDP Select Units:Amount every KDP Select-enrolled title earned monthly through Kindle Unlimited (KU) and the Kindle Owners’ Lending Library (KOLL). If a customer reads pages in your book for the first time through KU or KOLL, you will see a separate line item indicating the accumulated number of pages read under the column “Kindle Edition Normalized Pages (KENP) Read,” and the royalty earned through KU and KOLL under the “Royalty” column.

  • Free – Promotion:Free downloads due to Free promotion campaign(s) through KDP Select.

  • Free – Price Match:Free downloads due to competitor free price match.

 

SOURCE:  https://kdp.amazon.com/en_US/help/topic/G201541130

Advertisements

Read Full Post »


Three Scenarios for the Scaling up Potential of LPBI Group’s BioMed e-Series: Lights on Intellectual Property Growth Capacity and the Business Potential of the Venture

Author: Aviva Lev-Ari, PhD, RN

 

From: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Date: October 20, 2018 at 10:36:21 AM EDT

To: Gail Thornton <gailsthornton@yahoo.com>, “Dr. Larry Bernstein” <larry.bernstein@gmail.com>, Stephen J Williams <sjwilliamspa@comcast.net>

Cc: Marcus Feldman <mfeldman@stanford.edu>, rmandahl@gmail.com, Justin MDMEPhD <jdpmdphd@gmail.com>, Tilda Barliya <tildabarliya@gmail.com>, “Dr. Irina Robu, PhD” <irina.stefania@gmail.com>, “Dr. Raphael Nir” <rnir@sbhsciences.com>, “Dr. Dror Nir” <drornir0305@gmail.com>, Dee Sag <demet.sag@gmail.com>, Sudipta Saha <sudiptasaha1977@gmail.com>

Subject: Re: Dr. Laura Carfang from SurvivingBreastCancer.org interested in your Voices project

 

Dr. Larry, Dr. Williams, Gail

 

I wish to thank Dr. Williams for exposing to SurvivingBreastCancer.org

Our Series E: Parient-centered Medicine, Volume One: Voices of Patients, an e-Book on patients personal experiences with invasive surgical procedures, chiefly, cancerous organ excision and open heart surgery.

This Volume one is unique and please all read again the Preface, Introduction, Summary and Epilogue. Read in the follwoing link:

https://pharmaceuticalintelligence.com/biomed-e-books/series-e-titles-in-the-strategic-plan-for-2014-1015/2014-the-patients-voice-personal-experience-with-invasive-medical-procedures/

and

Co-Editors: Dr. Larry H. Bernstein and Gail Thornton

 

As Editor-in-Chief, I made the selection of the editors and envisioned the following unique features of this e-book:

  • Commissioned Gail to conduct interviews with Patients and to author articles that provide primary patients accounts. One article of Gail is on a cardiac patient, the rest on several cancer types, non on Breast Cancer
  • Gail, as Volume Co-Editors suggested to conduct interviews with Hospital CEOs around the Globe, I.e., Singapore, Switzerland, US: CA, NJ
  • Commissioned Dr. Larry to contribute articles on “The MD as a Cancer Patient”
  • Identified another “MD as a cancer patient”, Finding My Voice: A Laryngectomee’s Story
  • Identified two authors, for cardiac patients experience, one with open heart surgery, the other about a cardiac medical device in usage

As such, Series E: Volume One is a very distinctive e-Book. Gail Thornton and myself discussed marketing the e-Book in Cancer Treatment Centers in the US. The e-Book is priced for patients as e-readers ($49, 824 pages vs $75 or $115 for volumes of 2,000 – 3,000 pages or more)

I personally, planned this volume to be an e-Book widely marketed and read by the public at large. The other 15 volumes are of interest to the public, they are primarily for the Heath Care sector professionals, policy makers in Heath Care, Science and Research Administrators, Scientists, the entire GLOBAL and American Medical community.

Our BioMed e-Series Plan: SIXTEEN volumes to be completed in July 2019 and reach the Milestone of EXIT and ownership transfer in 12/2019 to 12/2020, time frame.

Dr. Lev-Ari gave Series E its Title and the Titles to Volume 1,2,3,4 in this e-Series. That was the case with all other four e-Series: 

https://pharmaceuticalintelligence.com/biomed-e-books/

  • Series A: Cardiovascular, six volumes, 

Content Consultant, Dr. J.D. Pearlman

  • Series B: Genomics, two volumes, 

Content Consultant, Prof. M.W. Feldman, Stanford University

  • Series C: Cancer, two volumes, 

Content Consultant, Dr. L.H. Bernstein

  • Series D: Metabolomics, Immunology, Infectious Diseases, 

Content Consultant, Dr. L.H. Bernstein

  • Series E: Patient-centered Medicine, four volumes

Content Consultant, Dr. L.H. Bernstein

 

This e-mail is about an organization, I.e., SurvivingBreastCancer.org expressing interest to support 

—–>>> A NEW e-BOOK, in Series E, Volume One: Patient Voices

To focus on the VOICES of Survivors of Breast Cancer as 2nd Edition to Volume One.

This volume, if produced, will be #17.

  • The initial 16-Volume BioMed Series did not plan on 2nd Editions to each Volume.

 

In light of SBC INTEREST, I see three Scenarios:

 

Scenario #1 limited LPBI Group involvement beyond LPBI Group Intellectual Property:

SurvivingBreastCancer.org (SBC) is given by fiat for being .org LPBI Group’s permission to use our methods in e-Publishing. They choose the Editor and they produce by their Editor and writers of their choice a volume IN THE IMAGE of Series E, Volume One 1st Edition. 

Here we own two IP assets

1.1 MIRROR IMAGE OF THE e-Table of Contents (eTOCs) of Volume One 1st Edition

1.2 The Curation methodology and all Formats, as perfected in 16-volume BioMed e-Series

Scenario #2 more involvement by LPBI Group

2.1 All of mentioned in #1 Scenarios

and

2.2. Dr. Williams provides SBC with a Bibliography in descending date of publishing of ALL Breast Cancer articles in the Archive of pharmaceuticalintelligence.com – all 5,400 articles in the Journal Archive are 100% IP of LPBI Group.

 

Scenario #3 LPBI Group becomes a BUSINESS PARTNER for SBC on the production of LPBI Group’s BioMed e-Series, Series E, 

Volume One 2nd Edition on VOICES of Patients of Breast Cancer Survivors

 

Other Options using LPBI Group Intellectual Property – very attractive proposition for potential transfer of ownership, aka, EXIT

  • eTOCs of Series E, Volume One, 1st Edition
  • The methodology of Curation and all Formats
  • Bibliography in descending date of Publication of articles on the CANCER TYPE from LPBI Group’s Archive of pharmaceuticalintelligence.com

Collaboration and Partnership with Patient Advocacy Foundations to support the following: Scaling up “Digital Library” Options on VOICES of Patients by TYPE of CANCER

  • Volume One 3rd Edition on VOICES of Patients of Prostate Cancer Survivors
  • Volume One 4th Edition on VOICES of Patients of Lymphomas and Leukemias
  • Volume One 5th Edition on VOICES of Patients of Lung Cancer 
  • Volume One 6th Edition on VOICES of Patients of Brain, Head and Neck Cancers
  • Volume One 7th Edition on VOICES of Patients of Pancreas, Liver and Biliary System Cancers
  • Volume One 8th Edition on VOICES of Patients of GI and Colonrectal 
  • Volume One 9th Edition on VOICES of Patients of Skin Cancers
  • Volume One 10th Edition on VOICES of Patients of Myelomas (Bone), Sarcomas and rare 
  • Connective tissue cancers
  • Volume One 11th Edition on VOICES of Patients of Kidney and Bladder Cancers and the GU system
  • Volume One 12th Edition on VOICES of Patients of Reproductive Organ Cancers: Ovarian, Cervical and Testicular 

BioMed e-Series 16 volumes could have TEN Editions each, Aviva can specify all these e-Book Titles on behalf of a Publisher(s).

  • 160 new titles. For a PUBLISHER, this is a gold mine.

SAME, as these Options for NEW Editions for Series E, Volume One, LPBI Group will draft Options for NEW Editions for

  • Series A – six volume times TEN Editions per Volume
  • Series B – two volumes times TEN Editions per Volume
  • Series C – two volumes times TEN Editions per Volume
  • Series D – three volume times TEN Editions per Volume
  • Series B – four volumes times TEN Editions per Volume

Thank you

Aviva Lev-Ari, PhD, RN

Editor-in-Chief, BioMed e-Series

http://PharmaceuticalIntelligence.com

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Read Full Post »


BioMed e-Series: 16 Volumes – electronic Table of Contents (eTOCs) of each Volume

Curator: Aviva Lev-Ari, PhD, RN

CLICK on the RED Link to review eTOCs of each Volume on LinkedIn

CLICK on the BLUE Link to review eTOCs of each Volume on Amazon.com

CLICK on the GREEN Link to review DETAILED eTOCs of each Volume

on https://pharmaceuticalintelligence.com/

 

Series A: e-Books on Cardiovascular Diseases

Series Content Consultant: Justin D Pearlman, MD, PhD, FACC

Volume 1,2,3,4,5,6

Volume 1:

Perspectives on Nitric Oxide in Disease Mechanisms

http://www.amazon.com/dp/B00DINFFYC

https://www.linkedin.com/pulse/perspectives-nitric-oxide-disease-mechanisms-table-aviva/

https://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/perspectives-on-nitric-oxide-in-disease-mechanisms-v2/

 

Volume 2:

Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation

http://www.amazon.com/dp/B018Q5MCN8

https://www.linkedin.com/pulse/cardiovascular-original-research-cases-methodology-aviva/

https://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/volume-two-cardiovascular-original-research-cases-in-methodology-design-for-content-co-curation/

 

Volume 3:

Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

http://www.amazon.com/dp/B018PNHJ84

https://www.linkedin.com/pulse/etiologies-cardiovascular-diseases-epigenetics-lev-ari-phd-rn/

https://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/volume-three-etiologies-of-cardiovascular-diseases-epigenetics-genetics-genomics/

 

Volume 4:

Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases

http://www.amazon.com/dp/B019UM909A

https://www.linkedin.com/pulse/regenerative-translational-medicine-therapeutics-lev-ari-phd-rn/

https://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/volume-four-therapeutic-promise-cvd-regenerative-translational-medicine/

 

Volumes 5:

Pharmacological Agents in Treatment of Cardiovascular Diseases (Series A: Cardiovascular Diseases Book 5)

https://www.amazon.com/dp/B07MGSFDWR

 

https://www.linkedin.com/post/edit/pharmacological-agents-treatment-cardiovascular-book-aviva

https://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/volume-five-pharmaco-therapies-for-cvd/

 

Volume 6:

Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment (Series A: Cardiovascular Diseases Book 6)

https://www.amazon.com/dp/B07MKHDBHF

https://www.linkedin.com/pulse/interventional-cardiology-disease-diagnosis-cardiac-lev-ari-phd-rn/

https://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/volume-six-interventional-cardiology-and-cardiac-surgery/

Series B: Frontiers in Genomics Research

Series Content Consultant: Prof. Marcus Feldman, Stanford University

Volume 1:

Genomics Orientations for Personalized Medicine

http://www.amazon.com/dp/B018DHBUO6 

https://www.linkedin.com/pulse/genomics-orientations-personalized-medicine-table-lev-ari-phd-rn/?published=t

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

 

Volume 2 – will be published in 2019 – eTOCs is Work-in-Progress

 

Series C: e-Books on Cancer & Oncology

Series Content Consultant: Larry H Bernstein, MD, FCAP

 

Volume 1:

Cancer Biology and Genomics for Disease Diagnosis 

http://www.amazon.com/dp/B013RVYR2K 

https://www.linkedin.com/pulse/cancer-biology-genomics-disease-diagnosis-table-lev-ari-phd-rn/

https://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/cancer-biology-and-genomics-for-disease-diagnosis/

 

Volume 2:

Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

http://www.amazon.com/dp/B071VQ6YYK 

https://www.linkedin.com/pulse/cancer-therapies-metabolic-genomics-interventional-lev-ari-phd-rn/?published=t

https://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/volume-2-immunotherapy-in-oncology/

 

Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases

Series Content Consultant: Larry H Bernstein, MD, FCAP

 

Volume 1:

Metabolic Genomics & Pharmaceutics electronic Table of Contents

http://www.amazon.com/dp/B012BB0ZF0 

https://www.linkedin.com/pulse/metabolic-genomics-pharmaceutics-electronic-table-lev-ari-phd-rn/

https://pharmaceuticalintelligence.com/biomed-e-books/series-d-e-books-on-biomedicine/metabolic-genomics-pharmaceutics/

 

Volume 2:

Infectious Diseases and Therapeutics e-Table of Contents, Volume 2

https://www.amazon.com/dp/B075CXHY1B 

https://www.linkedin.com/pulse/infectious-diseases-therapeutics-e-table-contents-2-lev-ari-phd-rn/

https://pharmaceuticalintelligence.com/biomed-e-books/series-d-e-books-on-biomedicine/human-immune-system-in-health-and-in-disease/

Volume 3:

The Immune System and Therapeutics 

https://www.amazon.com/dp/B075CXHY1B 

https://www.linkedin.com/pulse/immune-system-therapeutics-e-table-contents-aviva-lev-ari-phd-rn/?published=t

https://pharmaceuticalintelligence.com/biomed-e-books/series-d-e-books-on-biomedicine/human-immune-system-in-health-and-in-disease/

Series E: Patient-Centered Medicine

Series Content Consultant: Larry H Bernstein, MD, FCAP

 

Volume 1:

The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families

https://www.amazon.com/dp/B076HGB6MZ 

https://www.linkedin.com/pulse/voices-patients-hospitals-ceos-health-care-providers-aviva/

https://pharmaceuticalintelligence.com/biomed-e-books/series-e-titles-in-the-strategic-plan-for-2014-1015/2014-the-patients-voice-personal-experience-with-invasive-medical-procedures/

 

Volume 2:

Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders

https://www.amazon.com/dp/B078313281 

https://www.linkedin.com/pulse/medical-scientific-discoveries-21st-century-leaders-lev-ari-phd-rn/

https://pharmaceuticalintelligence.com/biomed-e-books/series-e-titles-in-the-strategic-plan-for-2014-1015/2014-interviews-with-scientific-leaders/

 

Volume 3:

Milestones in Physiology – Discoveries in Medicine, Genomics and Therapeutics Patient-centric Perspective

http://www.amazon.com/dp/B019VH97LU 

https://www.linkedin.com/pulse/milestones-physiology-discoveries-medicine-genomics-aviva/

https://pharmaceuticalintelligence.com/biomed-e-books/series-e-titles-in-the-strategic-plan-for-2014-1015/2014-milestones-in-physiology-discoveries-in-medicine/

 

Volume 4

Medical 3D BioPrinting – The Revolution in Medicine -Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices

https://www.amazon.com/dp/B078QVDV2W

https://www.linkedin.com/pulse/medical-3d-bioprinting-revolution-medicine-from-rd-lev-ari-phd-rn/?published=t

https://pharmaceuticalintelligence.com/biomed-e-books/series-e-titles-in-the-strategic-plan-for-2014-1015/volume-four-medical-3d-bioprinting-the-revolution-in-medicine/

 

BioMed e-Series

https://pharmaceuticalintelligence.com/biomed-e-books/

BioMed e-Series

In summary, WE ARE ON AMAZON.COM

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

https://www.amazon.com/s/ref=dp_byline_sr_ebooks_9?ie=UTF8&text=Aviva+Lev-Ari&search-alias=digital-text&field-author=Aviva+Lev-Ari&sort=relevancerank

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

http://www.amazon.com/dp/B071VQ6YYK

https://www.amazon.com/dp/B075CXHY1B

https://www.amazon.com/dp/B076HGB6MZ

https://www.amazon.com/dp/B078313281

https://www.amazon.com/dp/B078QVDV2W

https://www.amazon.com/dp/B07MGSFDWR

https://www.amazon.com/dp/B07MKHDBHF

Read Full Post »


Our 15 e-Books in Genomics and Medicine on Display at the Publication Desk of CHI @CHI’s 14th Annual Discovery on Target taking place September 19 – 22, 2016 in Boston, Westin Boston Waterfront

Editor-in-Chief, BioMed e-Series, LPBI Group: Aviva Lev-Ari, PhD, RN

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a Media Partner of CHI for CHI’s 14th Annual Discovery on Target taking place September 19 – 22, 2016 in Boston, Westin Boston Waterfront

 

DOT-646x200

attend

http://www.DiscoveryOnTarget.com

  • CHI’s Discovery on Target in Boston, September 19-22, 2016,

  • CRISPR: Mechanisms to Applications on 9/19/2016

 

other CHI’s Media Partners for this event are:

See us on the left to Nature

http://www.discoveryontarget.com/Discoveryontarget_content.aspx?id=125312

 

SEE Our 15 e-Books in Genomics and Medicine on Display at the Publication Desk of CHI’s Booth

 

flyersbcde-dot16

flyer-for-series-a-dot16

FORTHCOMING in 2016 & 2017

NEW e-Books on Amazon.com

flyersabcd2-dot16future

flyersseiesedot16future

 

BioMed e-Series

https://pharmaceuticalintelligence.com/biomed-e-books/

BioMed e-Series

WE ARE ON AMAZON.COM

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

BioMedical e-Books e-Series:

Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine

https://pharmaceuticalintelligence.com/biomed-e-books/

2013 e-Book on Amazon.com

  • Perspectives on Nitric Oxide in Disease Mechanisms, on Amazon since 6/2/12013

http://www.amazon.com/dp/B00DINFFYC

2015 e-Book on Amazon.com

 

http://www.amazon.com/dp/B012BB0ZF0

  • Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, on Amazon.com since 12/27/2015

http://www.amazon.com/dp/B019VH97LU

  • Cardiovascular, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, on Amazon since 11/30/2015

http://www.amazon.com/dp/B018Q5MCN8

  • Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics, on Amazon since 11/29/2015

http://www.amazon.com/dp/B018PNHJ84

  • Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases, on Amazon since 12/26/2015

http://www.amazon.com/dp/B019UM909A

 

2016 & 2017 Plan

2016 Expected Publications 

  • Series C: Cancer Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery – Conversion Format Stage

 

  • Series E: Volume 2: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific LeadersConversion Format stage

 

  • Genomics Volume Two on NGS – Dr. Williams and Aviva Lev-Ari, PhD, RN – work-in-Progress

2016 & 2017, We will continue with

– Aviva will work with Dr. Larry H Bernstein on CVD 5: Pharmacology-Therapy, 

–Aviva will work with Dr. Larry H Bernstein on CVD 6: Cardiac Surgery and Interventional Cardiology

– Dr. Pearlman alone: 

Four CVD Hardcopy Volumes, 1-Etiology, 2-Diagnostics, 3-Therapies, 4- Cardiac Imaging

Series E: Patient-centered Medicine

Content Consultant: Larry H Bernstein, MD, FCAP

Volume 1: The VOICES of Patients, HealthCare Providers, Care Givers and Families: Personal Experience with Critical Care and Invasive Medical Procedures – Work-in-Progress

Author, Curator and Editor: Larry H Bernstein, MD, FCAP and Gail Thornston, PhD(c)

Volume 2: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders – Conversion Format stage

Author, Curator and Editor: Larry H Bernstein, MD, FCAP

Volume 3: Milestones in Physiology & Discoveries in Medicine and Genomics, on Amazon.com since 12/27/2015

Author, Curator and Editor: Larry H Bernstein, MD, FCAP

http://www.amazon.com/dp/B019VH97LU

Volume 4:  Medical 3D BioPrinting – The Revolution in Medicine – Work-in-Progress

Editors:  Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

Read Full Post »